CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union
Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo
16.06.2023 - Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3 VALOR-HCM study to the U.S. Prescribing Information for .
Bristol-Myers Squibb (BMY) Announces FDA Approval of Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS Label streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
VALOR HCM is the second study to show that mavacamten can significantly reduce symptoms of obstructive hypertrophic cardiomyopathy, which includes left ventricular outflow tract.